Apmonia Therapeutics develops targeted biomolecular therapies that enhance the efficacy of cancer treatments while reducing adverse side effects. The company focuses on creating precise treatment strategies for various cancer types, improving patient outcomes through tailored therapeutic approaches.
Funding
$7.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EAFounders
Product
Problem
Solid tumors create a dense extracellular matrix (ECM) that protects cancer cells, enabling them to proliferate, adapt, evade therapies, and spread. Current cancer therapies often fail to effectively target this protective microenvironment.
Solution
Apmonia Therapeutics is developing a pipeline of targeted therapies against various solid cancers by specifically and selectively targeting the tumor microenvironment. The company's approach involves computational engineering of proteins and peptides, combined with cutting-edge screening and validation technologies, to disrupt the tumor ECM. This disruption makes cancer cells more vulnerable to treatment. Apmonia's lead program, TAX2, is a first-in-class peptide that modulates the tumor microenvironment by targeting the TSP-1/CD47 interaction and is about to enter clinical development. The company is also leveraging its in silico discovery platform to identify new therapeutic targets derived from the ECM and optimize the design of antagonistic peptides.
Target Audience
The primary target audience includes patients with difficult-to-treat solid cancers, as well as oncologists and researchers seeking new therapeutic strategies.
Features
- First-in-class drug candidate TAX2, a peptide that acts as a modulator of the tumor microenvironment by targeting the TSP-1/CD47 interaction
- Proprietary in silico discovery platform for identifying new therapeutic targets in the ECM
- Computational engineering of proteins and peptides for optimized drug candidates
- Preclinical proof-of-concept in multiple solid cancers, including ovarian cancer
- Development of a range of novel peptides targeting the ECM